Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Lantern Pharma Inc.
< Previous
1
2
Next >
Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer
March 28, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars
March 21, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights
March 20, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting
March 15, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET
March 13, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank
March 13, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors
March 09, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers
March 06, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials
March 02, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352
February 27, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates
February 15, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023
January 17, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma
January 05, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting
December 15, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)
December 13, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting
November 22, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights
November 07, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Management to Present at Upcoming Investor Conferences in Q4
November 02, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Report Third Quarter 2022 Operating & Financial Results on November 7, 2022 at 4:30 p.m. ET
October 31, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Present New Preclinical Data at Three Upcoming Scientific Conferences
October 25, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET
October 21, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300
October 20, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Present at Upcoming Investor Conferences
October 05, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting
September 23, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D.
September 19, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer
September 14, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma CEO & President, Panna Sharma, to Speak at H.C. Wainwright’s 24th Annual Global Investment Conference in September 2022
August 30, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights
August 08, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4:30 p.m. ET
August 01, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer
July 14, 2022
From
Lantern Pharma Inc.
Via
Business Wire
Tickers
LTRN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.